294 related articles for article (PubMed ID: 21835542)
1. Salinomycin inhibits osteosarcoma by targeting its tumor stem cells.
Tang QL; Zhao ZQ; Li JC; Liang Y; Yin JQ; Zou CY; Xie XB; Zeng YX; Shen JN; Kang T; Wang J
Cancer Lett; 2011 Dec; 311(1):113-21. PubMed ID: 21835542
[TBL] [Abstract][Full Text] [Related]
2. Aberrant Wnt/β-catenin signaling and elevated expression of stem cell proteins are associated with osteosarcoma side population cells of high tumorigenicity.
Yi XJ; Zhao YH; Qiao LX; Jin CL; Tian J; Li QS
Mol Med Rep; 2015 Oct; 12(4):5042-8. PubMed ID: 26134785
[TBL] [Abstract][Full Text] [Related]
3. TSSC3 overexpression reduces stemness and induces apoptosis of osteosarcoma tumor-initiating cells.
Huang Y; Dai H; Guo QN
Apoptosis; 2012 Aug; 17(8):749-61. PubMed ID: 22610481
[TBL] [Abstract][Full Text] [Related]
4. IWR-1, a tankyrase inhibitor, attenuates Wnt/β-catenin signaling in cancer stem-like cells and inhibits in vivo the growth of a subcutaneous human osteosarcoma xenograft.
Martins-Neves SR; Paiva-Oliveira DI; Fontes-Ribeiro C; Bovée JVMG; Cleton-Jansen AM; Gomes CMF
Cancer Lett; 2018 Feb; 414():1-15. PubMed ID: 29126913
[TBL] [Abstract][Full Text] [Related]
5. Targeted salinomycin delivery with EGFR and CD133 aptamers based dual-ligand lipid-polymer nanoparticles to both osteosarcoma cells and cancer stem cells.
Chen F; Zeng Y; Qi X; Chen Y; Ge Z; Jiang Z; Zhang X; Dong Y; Chen H; Yu Z
Nanomedicine; 2018 Oct; 14(7):2115-2127. PubMed ID: 29898423
[TBL] [Abstract][Full Text] [Related]
6. Wnt, osteosarcoma, and future therapy.
Hoang BH
J Am Acad Orthop Surg; 2012 Jan; 20(1):58-9. PubMed ID: 22207519
[No Abstract] [Full Text] [Related]
7. Cancer stem cells in osteosarcoma.
Brown HK; Tellez-Gabriel M; Heymann D
Cancer Lett; 2017 Feb; 386():189-195. PubMed ID: 27894960
[TBL] [Abstract][Full Text] [Related]
8. Poly(lactic-co-glycolic acid) nanoparticles conjugated with CD133 aptamers for targeted salinomycin delivery to CD133+ osteosarcoma cancer stem cells.
Ni M; Xiong M; Zhang X; Cai G; Chen H; Zeng Q; Yu Z
Int J Nanomedicine; 2015; 10():2537-54. PubMed ID: 25848270
[TBL] [Abstract][Full Text] [Related]
9. Functionalized curcumin analogs as potent modulators of the Wnt/β-catenin signaling pathway.
Leow PC; Bahety P; Boon CP; Lee CY; Tan KL; Yang T; Ee PL
Eur J Med Chem; 2014 Jan; 71():67-80. PubMed ID: 24275249
[TBL] [Abstract][Full Text] [Related]
10. Dioscin inhibits stem-cell-like properties and tumor growth of osteosarcoma through Akt/GSK3/β-catenin signaling pathway.
Liu W; Zhao Z; Wang Y; Li W; Su Q; Jia Q; Zhang J; Zhang X; Shen J; Yin J
Cell Death Dis; 2018 Mar; 9(3):343. PubMed ID: 29497056
[TBL] [Abstract][Full Text] [Related]
11. The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor.
Riccioni R; Dupuis ML; Bernabei M; Petrucci E; Pasquini L; Mariani G; Cianfriglia M; Testa U
Blood Cells Mol Dis; 2010 Jun; 45(1):86-92. PubMed ID: 20444629
[TBL] [Abstract][Full Text] [Related]
12. Let-7d miRNA Shows Both Antioncogenic and Oncogenic Functions in Osteosarcoma-Derived 3AB-OS Cancer Stem Cells.
Di Fiore R; Drago-Ferrante R; Pentimalli F; Di Marzo D; Forte IM; Carlisi D; De Blasio A; Tesoriere G; Giordano A; Vento R
J Cell Physiol; 2016 Aug; 231(8):1832-41. PubMed ID: 26679758
[TBL] [Abstract][Full Text] [Related]
13. Salinomycin possesses anti-tumor activity and inhibits breast cancer stem-like cells via an apoptosis-independent pathway.
An H; Kim JY; Lee N; Cho Y; Oh E; Seo JH
Biochem Biophys Res Commun; 2015 Oct; 466(4):696-703. PubMed ID: 26407842
[TBL] [Abstract][Full Text] [Related]
14. WNT5B drives osteosarcoma stemness, chemoresistance and metastasis.
Perkins RS; Murray G; Suthon S; Davis L; Perkins NB; Fletcher L; Bozzi A; Schreiber SL; Lin J; Laxton S; Pillai RR; Wright AJ; Miranda-Carboni GA; Krum SA
Clin Transl Med; 2024 May; 14(5):e1670. PubMed ID: 38689429
[TBL] [Abstract][Full Text] [Related]
15. Salinomycin simultaneously induces apoptosis and autophagy through generation of reactive oxygen species in osteosarcoma U2OS cells.
Kim SH; Choi YJ; Kim KY; Yu SN; Seo YK; Chun SS; Noh KT; Suh JT; Ahn SC
Biochem Biophys Res Commun; 2016 Apr; 473(2):607-13. PubMed ID: 27033598
[TBL] [Abstract][Full Text] [Related]
16. Osteosarcoma Stem Cells Have Active Wnt/β-catenin and Overexpress SOX2 and KLF4.
Martins-Neves SR; Corver WE; Paiva-Oliveira DI; van den Akker BE; Briaire-de-Bruijn IH; Bovée JV; Gomes CM; Cleton-Jansen AM
J Cell Physiol; 2016 Apr; 231(4):876-86. PubMed ID: 26332365
[TBL] [Abstract][Full Text] [Related]
17. Mesenchymal stem cells promote osteosarcoma cell survival and drug resistance through activation of STAT3.
Tu B; Zhu J; Liu S; Wang L; Fan Q; Hao Y; Fan C; Tang TT
Oncotarget; 2016 Jul; 7(30):48296-48308. PubMed ID: 27340780
[TBL] [Abstract][Full Text] [Related]
18. Identification of DNA-PKcs as a primary resistance factor of salinomycin in osteosarcoma cells.
Zhen YF; Li ST; Zhu YR; Wang XD; Zhou XZ; Zhu LQ
Oncotarget; 2016 Nov; 7(48):79417-79427. PubMed ID: 27765904
[TBL] [Abstract][Full Text] [Related]
19. Transforming growth factor β1 signal is crucial for dedifferentiation of cancer cells to cancer stem cells in osteosarcoma.
Zhang H; Wu H; Zheng J; Yu P; Xu L; Jiang P; Gao J; Wang H; Zhang Y
Stem Cells; 2013 Mar; 31(3):433-46. PubMed ID: 23225703
[TBL] [Abstract][Full Text] [Related]
20. Histone methyltransferase SETD2 regulates osteosarcoma cell growth and chemosensitivity by suppressing Wnt/β-catenin signaling.
Jiang C; He C; Wu Z; Li F; Xiao J
Biochem Biophys Res Commun; 2018 Jul; 502(3):382-388. PubMed ID: 29842882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
